Making Old Drugs New Again with Specialized Biotech: DURECT Corp.'s James E. Brown
Source: George S. Mack of The Life Sciences Report  (1/27/16)
Sometimes wonderful ideas live on and create value for the ages. Alza Corp. was a pioneer in the field of drug delivery, and that illustrious heritage continues in its spinout, DURECT Corp., which has leveraged the technology to enable highly innovative, value-added products that may soon be on the market. In this interview with The Life Sciences Report, DURECT cofounder and CEO James E. Brown discusses his company's pipeline, and how DURECT is evolving into a high-margin, blockbuster biotech. More >

The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase
Source: Tracy Salcedo of The Life Sciences Report  (1/27/16)
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors. Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal. More >

Inception Mining's Diverse Batch of Assets Offers Production Now, Growth Later
Source: Brian Sylvester of The Gold Report  (1/26/16)
Inception Mining is producing gold at its Clavo Rico operation in Honduras and is preparing to begin contract gold mining at its U.P. & Burlington project in the mountains of Idaho. Add in resource expansion and some exploration upside in Nevada and you have a story with lots of interesting angles. Inception CFO and Director Trent D'Ambrosio shares with The Gold Report his company's plans to boost production and expand mine life at Clavo Rico. More >

Which Energy Companies Are Being Added to US Global Funds in Anticipation of an Oil Rebalance?
Source: JT Long of The Energy Report  (1/26/16)
There are still winners in the energy space, but you have to move quickly. In advance of the rebalance U.S. Global Investors CEO Frank Holmes is expecting toward the end of 2016, he and analyst Samuel Pelaez point to the sectors taking advantage of opportunities, including refiners, midstream MLPs, low-cost producers, airlines and chemical companies. In this interview with The Energy Report, they name their favorites and outline the fundamentals that will make 2016 look a lot different than the year that just ended. More >

Rick Mills: How to Profit from the Demands of a Growing World Population
Source: JT Long of The Gold Report  (1/21/16)
As the world prepares to house, feed and care for 9.7 billion people, Ahead of the Herd founder Rick Mills is looking for the companies that will profit from the silent tsunami of demand creeping up on resource and healthcare providers. In this interview with The Gold Report, Mills reveals the six companies he thinks are well positioned in their respective sectors to ride this population wave to profits. More >

The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News
Source: George S. Mack of The Life Sciences Report  (1/20/16)
Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. In some cases he will follow a company's clinical development program and data for years before he pulls the trigger and recommends a name. In this interview with The Life Sciences Report, Leong presents a number of names for investors' consideration. Many won't be mentioned in his usual write-ups: It's an early look at what's on his watch list and in his inbox. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place. More >

Chen Lin: Chinese Volatility Could Fuel a Lithium-Price Rocket Launch
Source: JT Long of The Energy Report  (1/19/16)
When China's stock market started cratering at the beginning of the year, veteran investor and newsletter writer Chen Lin was rubbing his hands in anticipation of the opportunities that would be opening up, particularly in lithium and natural gas. In this interview with The Energy Report, the author of What is Chen Buying? What is Chen Selling? shares his insights on what pushed battery-grade lithium prices up fourfold and which companies could benefit from a continued supply-demand imbalance. As a bonus, he also lists the three companies he thinks could take advantage of high overseas natural gas prices to actually return money to investors in the energy space. More >

Five Companies Swiss Asset Manager Florian Siegfried Is Watching
Source: JT Long of The Gold Report  (1/18/16)
When a leading Swiss bank recommended its clients sell all their gold, AgaNola Asset Manager Florian Siegfried knew the precious metal was preparing for an upswing. In this interview with The Gold Report, he shares five junior mining names that have made smart moves during the down time and are well positioned for an upswing. More >

Almaden: Succeeding in a Tough Resource Market with World-Class Management and Gold-Silver Discovery
Source: JT Long of The Gold Report  (1/13/16)
With approximately $5.5 million in the bank, a 3.5-million-ounce gold equivalent Measured and Indicated resource, zero debt and a robust, updated preliminary economic assessment, Almaden Minerals Ltd. CEO Morgan Poliquin says the company is in position to not only survive this tough market but to continue adding significant value at a deep discount. While other companies are trying to figure out how to keep the lights on, Almaden has been active. The company recently completed a spinout of a large portfolio of exploration projects and royalties—including a royalty on Ixtaca—into Almadex Minerals Inc. and purchased an option on a mint condition mill that reduced the initial capital cost estimate by some $70 million. In this interview with The Gold Report, the second-generation geologist points to the fact that 95% of the Tuligtic property, which hosts the Ixtaca Zone, remains unexplored and that the company can drill for about a third of what most operators pay. He says that the company’s market cap is less than the savings from the purchase of the mill, as an indication that a potential buyout is a plausible scenario. More >

A Bucket of Canadian Stocks Set to Soar in 2016: Euro Pacific Canada's Doug Loe
Source: Staff of The Life Sciences Report  (1/13/16)
The new year is off to a turbulent start, with indices across all markets, including biotech, sliding downward in the face of headwinds from China. Canadian healthcare stocks offer a windbreak for biotech investors, however, especially if they select a diversified basket across the various sectors. In this interview with The Life Sciences Report, Euro Pacific Canada's Doug Loe details a basket of Canadian companies that offer shelter from the storm. More >

How Does Jayant Bhandari Maximize Returns and Minimize Risk?
Source: Brian Sylvester of The Gold Report  (1/11/16)
Sometimes a market in turmoil offers opportunity. Independent investment adviser Jayant Bhandari regularly sifts through bourses to find opportunities that maximize his reward for the least amount of risk. Bhandari currently sees two paths to value: companies that were either oversold in heavy tax-loss selling late in 2015 or in the "free upside" offered in arbitrage situations. In this interview with The Gold Report, Bhandari explains why much of the world's populace is already chasing gold and why a smattering of junior gold equity names offer more than what a market in turmoil might suggest. More >

Major Medical Journal Publishes Data from BrainStorm Stem Cell Study
Source: Staff of The Life Sciences Report  (1/11/16)
There is no cure for ALS, a debilitating and ultimately fatal neurological disease. But BrainStorm Cell Therapeutics Inc.'s NurOwn stem cell platform, currently in clinical trials, solicited responses in some patients, resulting in publication of a paper in the prestigious Journal of the American Medical Association, according to a company press release. BrainStorm made the credibility-building announcement on the opening day of major biotech conferences in San Francisco. More >

Why Is Charles Gibson Nervous About the Fed's Actions?
Source: Brian Sylvester of The Gold Report  (1/7/16)
Charles Gibson, an analyst with London-based Edison Investment Research, is nervous. Gibson says the U.S. Federal Reserve's statement that it would push the benchmark interest rate to 1.375% by the end of 2016 could send the U.S. economy in the wrong direction for the sake of containing mostly nonexistent inflation. He says the economy's capacity to sustain higher interest rates—especially higher real interest rates—is limited and that could ultimately create greater safe-haven investment demand for gold. In light of some choppy economic times ahead, Gibson and his colleague Tom Hayes recommend defensive equity names with little risk in this interview with The Gold Report. More >

Immunotherapy Inside the Cell: Three Companies on Their Way to the 'Holy Grail' of Cancer Treatment
Source: Tracy Salcedo of The Life Sciences Report  (1/6/16)
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. to introduce autologous immunotherapy intracellularly "opens a whole dimension." Dorman Followwill of Frost & Sullivan suggests this new approach could shift the focus from "therapy" to "cure," with rewards for the companies leading the way. In this article, The Life Sciences Report explores the possibilities of these new technologies—and the prospects for companies like Sorrento, Inovio Pharmaceuticals Inc. and OncoSec Medical Inc.—with Lin, Followwill and Ram Selvaraju of Rodman and Renshaw. More >

Dundee's David Talbot Says Green Energy Trend Is Your Friend
Source: Brian Sylvester of The Energy Report  (1/5/16)
David Talbot of Dundee Capital Markets forecasts uranium demand growth of about 6% compounded annually through 2020, which ought to be more than enough to kickstart depressed U3O8 prices. Nuclear energy is part of a growing trend away from fossil fuels toward green energy and things like lithium-ion batteries for cars and energy storage. Talbot explains that lithium demand is expected to grow even faster than uranium demand, and the market is already undergoing a supply deficit. In this interview with The Energy Report, he offers his top picks in the uranium and lithium spaces, as well as a graphite name, all poised to ride the green energy trend higher. More >

Gold Standard Ventures Is Uncovering Bonanza Grades in Nevada's Carlin Trend
Source: JT Long of The Gold Report  (1/4/16)
In the wake of what has been described as "obscene" intersects at Gold Standard Ventures' newly consolidated Railroad-Pinion project and a corresponding jump in the share price, CEO Jon Awde shares with The Gold Report readers his plans for moving the project forward in 2016. More >

Veteran Investor Rick Rule Reveals a Unique Arbitrage Opportunity
Source: Karen Roche of The Gold Report  (1/4/16)
One of the hardest things for a mining executive to do may be nothing. But in a market that is not rewarding companies for pulling resources out of the ground, Sprott US Holdings Inc. CEO Rick Rule would prefer to see what he calls "optionality" rather than dilution from companies looking to justify salaries. In this interview with The Gold Report, he praises innovative precious metals streams on base metal projects and one Canadian company that is adding value and being rewarded for it. More >

A Year of Tips for Winning the Natural Resource Investment War
Source: The Energy Report Staff   (12/29/15)
Energy investors are no strangers to boom-and-bust cycles. In fact, a number of the experts interviewed by The Energy Report in 2015 took a certain amount of glee in the opportunities they knew would open up in low-price markets for oil and gas, uranium and lithium. Let's take a trip around the world as we recall the words of wisdom these experts shared, and see if they can spark a better understanding of what we can expect during the next turn around the sun. More >

2015: A Year of Investing Perspective
Source: The Gold Report Staff  (12/28/15)
As we at The Gold Report interviewed the investing stars in 2015, we saw some patterns develop. Whether it was in the wake of terror attacks, bond defaults, currencies (we are looking at you, Swiss Central Bank and China, decoupling from the euro and dollar respectively), political drama in the U.S., Iran, Turkey, Ukraine and Germany or the long-rumored Federal Reserve interest rate hike, the call seemed to be for patience. Crises come and go, cycles have their way with commodities and then move on only to return again under another headline. Smart investors, according to the experts we interviewed, know that the way to weather these storms is to be diversified. The way to profit from them is to be contrarian. Let's take a stroll down memory lane and see what it tells us about the road ahead. More >

Why CSR Makes Sense for Communities, Companies and Investors
Source: JT Long of The Gold Report  (12/24/15)
Mining companies and their shareholders have come to the realization that doing the right things in the communities where they operate is important for a lot of reasons, including the bottom line. Mining executives also tell The Gold Report that the most effective corporate social responsibility (CSR) programs are orchestrated cooperatively instead of applied prescriptively. More >

Growth by Acquisition Is Solid: Russell Stanley of Mackie Research Capital
Source: George S. Mack of The Life Sciences Report   (12/23/15)
The traditional biotech investor wants to hit the lottery with a blockbuster molecule, but there are less risky avenues to profit, where capital is deployed to leverage the healthcare market via reimbursement from Medicare, the Affordable Care Act and private-pay insurance. In this interview with The Life Sciences Report, Russell Stanley of Mackie Research Capital tells investors that growth is where you find it, including in acquisitions. Stanley offers three names that, based on his current target prices, offer investors potential returns of more than 100%. More >

Gear Up for a Violent Uranium Price Spike: Cantor Fitzgerald's Rob Chang
Source: Kevin Michael Grace of The Energy Report  (12/22/15)
The price of uranium is still in the doldrums, but that will change soon—and violently, says Rob Chang of Cantor Fitzgerald Canada. In this interview with The Energy Report, he explains that electric utilities will begin to run short of fuel even before 2020, when 33 additional reactors are expected to come on line. With that in mind, Chang predicts that prices could triple in the next few years, and highlights a half-dozen equities that will likely supply the increased demand and thereby deliver multiples to investors. More >

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary
Source: Gail Dutton of The Life Sciences Report  (12/22/15)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (AEMD:NASDAQ), is pioneering the potential use of an exosome-based biomarker to diagnose chronic traumatic encephalopathy (CTE), a condition that otherwise can only be identified postmortem. As James "Jim" Joyce, executive chairman, tells The Life Sciences Report, other companies are exploring this approach in oncology, but Exosome Sciences is the only company advancing an exosome-based candidate to diagnose CTE. More >

Cantor Fitzgerald's Rob Chang Names Four Miners that Can Survive $1,050 Gold and $15 Silver
Source: Kevin Michael Grace of The Gold Report  (12/21/15)
The price of gold has see-sawed since the Federal Reserve raised interest rates on Dec. 16, and market experts debate if the action is good or bad for gold. Rob Chang of Cantor Fitzgerald Canada believes that after the small rate hike doomsayers are overstating their case and that gold should sell in 2016 for about $100/oz more than today. In this interview with The Gold Report, he argues that in today's climate cash costs below $1,000/oz are the bare minimum requirement for survival. Happily, Chang highlights three gold producers and one silver producer that have what it takes. More >

RestorGenex and Diffusion Pharmaceuticals Announce Merger to Form Oncology Biotech Company
Source: The Life Sciences Report Staff   (12/21/15)
The merger of RestorGenex Corp. (RESX: OTCQX) and privately held Diffusion Pharmaceuticals LLC, announced Tuesday, Dec. 15, will create an oncology-focused clinical-stage company with a diversified development portfolio of product candidates addressing novel targets, including several orphan indications, according to a press release issued by the companies. The combined company will be named Diffusion Pharmaceuticals Inc. and will be headquartered in Charlottesville, Virginia. More >